Methoxy polyethylene glycol-epoetin beta biosimilar - Intas Biopharmaceuticals

Drug Profile

Methoxy polyethylene glycol-epoetin beta biosimilar - Intas Biopharmaceuticals

Latest Information Update: 04 Nov 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intas Biopharmaceuticals
  • Class Antianaemics; Colony-stimulating factors; Erythropoietins; Haematopoietic cell growth factors; Polyethylene glycols
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Anaemia

Most Recent Events

  • 04 Nov 2013 Clinical trials in Anaemia in India (SC)
  • 04 Nov 2013 Intas Biopharmaceuticals plans a phase III trial for Anaemia associated with chronic kidney disease in India (CTRI2013-09-003956)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top